New Tools Increase Accessibility to High Content Screening Assays By Dr John Comley There have been major improvements in the instrument offerings and tools that enable high content screening (HCS) over the past decade. In this review we examine the status of high… Read More
Ubiquitination, E3 Ligases and Drug Discovery – Novel technologies for a challenging pathway By Dr Neil Wilkie and Dr Steve Davies Does ubiquitin drug discovery provide the opportunity for a new class of therapeutic agents? This article argues that new technological advances are removing many of the… Read More
Stem Cells: Cell-Based Assays and the World of Small Molecules By Dr Christina N. Ramirez, Dr Dana C. Duré and Dr Hakim Djaballah Stem cells remain a hot topic in academia and industry alike, and with the potential to cause a paradigm shift where many believe in their… Read More
Innovate While Derisking Drug Development: Yes We Can! Taher Abbasi, Pradeep Fernandes, Dr Shireen Vali and Professor Gurkirpal Singh The outlook for the drug industry continues to remain bleak in context of productivity and success rates. In spite of ongoing increase in R&D expenses and technology revolutions in… Read More
By Dr Jeffrey Dage and Dr Kalpana Merchant While the jury is still out in terms of iPS cell technology and its ability to deliver a regenerative therapy or, indeed, contribute to the development of a clinical molecule, this paper argues that the progress by… Read More
The Information Symphony: Data orchestration for a changing industry managing data on a platform for innovation. By Chris Molloy A leading ballet conductor (1) recently told me of courses which he runs for senior business leaders. He allows them to conduct an orchestra: first, very strictly, with close… Read More
Pathway Analysis – Understanding the bridge between environmental cues and cellular response By Dr John Comley Understanding the function of a protein in the context of normal and abnormal cellular processes requires a comprehensive knowledge not only of its regulation but also of its role in signalling and… Read More
Optimising Well Results In Label-Free Analysis By Dr Stephan Heyse, Dr Oliver Leven and Dr Jon Tupy Bearing in mind the cost and time required to conduct a screening campaign, it is of paramount importance that screening laboratory scientists process and analyse screen data as carefully and consistently… Read More
Share Share Tweet Email Stem Cell Banks: Investing in the promise of cancer stem cell science Stem Cell Banks: Investing in the promise of cancer stem cell science By Madeline Page and Rosario Isasi The… Read More
Small Scale Benchtop Automation: Broadening the adoption of lab automation By Dr John Comley Driven by the need to enable technically challenging or repetitive processes, many labs in drug discovery that were not previously adopters of laboratory automation are being increasingly drawn to the potential of simple… Read More
Exploring the horizons of small molecule drug discovery the evolution and application of the ideal fragment library By Dr David Myszka and Dr Jane Paul With the pharmaceutical industry facing unprecedented challenges in small molecule drug discovery, this paper argues that, with the correct design of the… Read More
When High Content Screening Meets High Throughput By Dr Vincent Unterreiner and Dr Daniela Gabriel The terms High Content Imaging (HCI) and High Throughput Screening (HTS) were introduced more than a decade ago (1) and are defining the use of automated microscopy and automated image analysis in the… Read More
The Apocalyptic Horsemen of Drug Discovery and Development By Dr Gary J. Keil The pharmaceutical industry should consider an evolutionary disease management approach based on homeostasis, irreversibility, biological alinearity, pseudo-N-of-1 health and disease states and narrative medicine best practices in order to help secure a successful drug… Read More
A roadmap for achieving self-sustainability of academic high throughput screening core facilities By Dr Peter R. McDonald, Dr Anuradha Roy and Dr Rathnam Chaguturu Many academic HTS centres, faced with the high costs of drug discovery and decreasing federal funding, are struggling to survive. Just as with… Read More
By Dr Aaron Heifetz The promise of stem cell technology as a tool for drug discovery, drug development and as a therapeutic modality is no longer in the future but part of contemporary healthcare. The speed which stem cells have… Read More
Targeting Target Cancer Metabolism – What is fuelling the resurgence? By Dr Neil P. Jones Targeting the metabolic pathways of cancer is a hot topic for drug discovery. The central dogma is that cancers have a higher demand for metabolic inputs to aid proliferation and survival and… Read More